Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 8;7(15):4019-4023.
doi: 10.1182/bloodadvances.2022009325.

Association of social deprivation with survival in younger adult patients with AML: an Alliance study

Melanie Rebechi  1 , Jessica Kohlschmidt  2   3 , Krzysztof Mrózek  2 , Deedra Nicolet  2   3 , Alice S Mims  2   4 , James S Blachly  2   4 , Shelley Orwick  4 , Karilyn T Larkin  1   2 , Christopher C Oakes  1   2 , Andrew Hantel  5 , Andrew J Carroll  6 , William G Blum  7 , Bayard L Powell  8 , Geoffrey L Uy  9 , Richard M Stone  5 , Richard A Larson  10 , John C Byrd  11 , Electra D Paskett  12 , Jesse J Plascak  12 , Ann-Kathrin Eisfeld  2   4
Affiliations

Association of social deprivation with survival in younger adult patients with AML: an Alliance study

Melanie Rebechi et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts-of-interest disclosure: A.S.M. received research funding from Leukemia and Lymphoma Society’s Beat AML clinical study, Aptevo, Daiichi Sankyo, Glycomemetics, Kartos Pharmaceuticals, Xencor, and Genentech; and is a consultant for Aptevo, AbbVie, BMS, Glycomemetics, Jazz Pharmaceuticals, Kura Oncology, and Syndax Pharmaceuticals. J.S.B. is a consultant for, and reported honoraria from, KITE, INNATE, AstraZeneca, and AbbVie. W.G.B. reported honoraria from AbbVie, Syndax, and AmerisourceBergen; and research funding from Celyad Oncology, Nkarta, Xencor, Forma Therapeutics, and Leukemia and Lymphoma Society. G.L.U. is a consultant for AbbVie, Agios, Jazz, GlaxoSmithKline, Genentech, and Novartis; reported honoraria from Astellas; and research funding from Macrogenics. R.M.S. consults for AbbVie, Agios, Aprea, Arog, Boston Pharmaceuticals, Bristol Myers Squibb, Celgene, Foghorn Therapeutics, GlaxoSmithKline, Innate, Janssen, Jazz, Macrogenics, Novartis, Onconova, and Takeda; received research funding from AbbVie, Agios, Arog, and Novartis; and serves on the advisory committee or board of directors for Actinium, Amgen, Astellas, BerGen Bio, Boston Pharmaceuticals, Elevate Bio, Gemoab, Syndax, Syntrix/ACI, and Syros. R.A.L. received research funding from Astellas, Cellectis, Gilead, Novartis, and Rafael Pharmaceuticals; and consults for AbbVie, CVS/Caremark, Epizyme, and Takeda. J.C.B. consults for Astellas, AstraZeneca, Novartis, Pharmacyclics, Syndax, and Trillium; receives honoraria from Astellas, AstraZeneca, Novartis, Pharmacyclics, Syndax, and Trillium; is a chairman of the scientific advisory board of Vincerx Pharmaceuticals and a member of the advisory committee of Newave; and is a current equity holder of Vincerx Pharmaceuticals. E.D.P. received research funding from Merck and Pfizer. A.-K.E. is a spouse of Christopher J. Walker who is currently employed by Karyopharm Therapeutics. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Geographic distribution and treatment outcomes of adults with AML with respect to SDI assignments, race, and genetic-risk profile. (A) Map of the United States with light-green to dark-green color scale indicating the calculated SDI based on patients’ home zip code. Dark color corresponds to lower SDI score. (B) OS of patients with AML aged <60 years with respect to their SDI grouping (high vs low). (C) Forest plot depicting final multivariable model for OS. (D) OS of patients with AML belonging to the favorable genetic-risk group of the 2017 European LeukemiaNet classification, comparing patients with high SDI with those with low SDI. (E) OS of high- vs low-SDI groups of patients with AML with respect to the patients’ self-reported race. Only 3 Black patients belonged to the low-SDI group and are not depicted in the graphic.
See this image and copyright information in PMC

References

    1. Rodriguez CP, Baz R, Jawde RA, et al. Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemia. Leuk Res. 2008;32(3):413–420. - PubMed
    1. Joshua TV, Rizzo JD, Zhang M-J, et al. Access to hematopoietic stem cell transplantation: effect of race and sex. Cancer. 2010;116(14):3469–3476. - PMC - PubMed
    1. Byrne MM, Halman LJ, Koniaris LG, Cassileth PA, Rosenblatt JD, Cheung MC. Effects of poverty and race on outcomes in acute myeloid leukemia. Am J Clin Oncol. 2011;34(3):297–304. - PubMed
    1. Borate UM, Mineishi S, Costa LJ. Nonbiological factors affecting survival in younger patients with acute myeloid leukemia. Cancer. 2015;121(21):3877–3884. - PubMed
    1. Bradley CJ, Dahman B, Jin Y, Shickle LM, Ginder GD. Acute myeloid leukemia: how the uninsured fare. Cancer. 2011;117(20):4772–4778. - PubMed

Publication types

Associated data